SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2019 Biotech Charity Contest

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (76)1/11/2019 10:35:15 PM
From: BulbaMan  Read Replies (1) of 280
 
1/11/2019 Contest update (for first 8 trading days of 2019)
(Obviously, last Friday’s 1/14/2019 date was a typo. Ooops!)
Despite the government shutdown (or maybe because of it), biotechs busted out of the gate to begin the year.
At Friday’s close, after 2019's first eight trading days, the Contest median was up an impressive 13.40%, the Nasdaq Biotech Index (NBI) was up 12.65%, the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 13.84% and the Nasdaq Composite Index (NCI) was up 5.07%.
HOOD’s portfolio remained in first place with an awe-inspiring 25.97% gain for the eight days. Almost as dazzling was performance of second place RKRW’s portfolio, up 24.12% YTD, with SANCTU’s portfolio, up 22.28% YTD, not far behind in third place.
At Friday's close, all 39 Contest portfolios were in the green, with 20 beating the NBI and 17 beating the SPSIBI.
The 167 Contest stock picks have an average YTD gain of 15.07% and a median YTD gain of 12.66%.
(As I expected, my own portfolio was quickly tossed out of the Top Ten. Responsible for its downfall was the worst performing stock for the year, CFRX. Ironically, CFRX’s nose-dive followed a very positive press release from the company, headlined: “ContraFect’s Exebacase [CF-301] Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study.” I’m not complainjng, just shaking my head.)
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the eight days ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.)
Portfolio adjustments: None.
(All corrections, especially adjustments for splits & mergers, greatly appreciated.)
Have a fun winter weekend biotechies!
Peace & good health,
Bulba

			1/11/19	
Rank Name Profit/Loss
1 HOOD 25,965
2 RKRW 24,122
3 SANCTU 22,280
4 DOUGH 20,271
5 JACKH 19,730
6 BIOADD 18,851
7 BIOMAV 16,461
8 BLADE 16,388
9 BIOCQR 15,709
10 ROBO 15,641

YTD's Top 5 Gainers
Symbol YE 2018 1/11/19 Wk.%chg.
CTIC 0.734 1.330 81.30%
CNST 4.010 6.980 74.06%
INSM 13.120 22.700 73.02%
EPZM 6.160 10.310 67.37%
LOXO 140.070 232.510 66.00%

YTD's Worst 5 Losers
Symbol YE 2018 1/11/19 Wk.%chg.
CFRX 1.530 0.610 -60.13%
SESN 1.420 0.763 -46.30%
PETX 6.130 4.370 -28.71%
SELB 2.660 2.390 -10.15%
ASLN 3.950 3.550 -10.13%
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext